Abstract
As a non-ergolinic dopamine agonist for transdermal administration, rotigotin is now available as an initial therapy or as combination therapy with L-dopa for the late stages of the disease. This form of administration makes its use independent of gastroparesis or dysphagia and thus opens a new option for perioperative situations. Furthermore, recent study results reveal a positive effect on early morning akinesia, dyskinesias/fluctuations and sleep disturbances associated with Parkinson's disease . Areas of application to be examined in the future are its influence on depressive disorders and its use in poorly compliant patients with Parkinson's disease, cognitive deficits or in cases of hallucinations and psychoses.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
